BCL2 and central nervous system cancer: In glioma cells that are resistant to temozolomide, it was demonstrated that the loss of miR-16 specifically can contribute to resistance in the U251MG/Temozolomide resistant cell line and that the blocking of miR-16 in the temozolomide sensitive AM38 cell line increased resistance by de-repressing BCL2 (105).